EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity

Xi Lv iD, Ran Chen, Taizhen Liang, Haojie Peng, Qiannan Fang, Shiqi Xiao, Sen Liu, Meilin Hu, Fei Yu, Lixue Cao, Yiwen Zhang, Ting Pan und 7 weitere

mBio · 2024

DOI: 10.1128/mbio.03358-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Xi Lv und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: COVID-19, Exosomes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: R&D Programs of Guangzhou National Laboratory, MOST | National Natural Science Foundation of China (NSFC), National Key R&D Program of Department of Science and Technology of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a global pandemic, which severely endangers public health. Our and others’ works have shown that the angiotensin-converting enzyme 2 (ACE2)-containing exosomes (ACE2-exos) have superior antiviral efficacies, especially in response to emerging variants. However, the mechanisms of how the virus counteracts the host and regulates ACE2-exos remain unclear. Here, we identified that SARS-CoV-2 nonstructural protein 6 (NSP6) inhibits the production of ACE2-exos by affecting the protein level of ACE2 as well as tetraspanin-CD63 which is a key factor for exosome biogenesis. We further found that the protein stability of CD63 and ACE2 is maintained by the deubiquitination of proteasome 26S subunit, non-ATPase 12 (PSMD12). NSP6 interacts with PSMD12 and counteracts its function, consequently promoting the degradation of CD63 and ACE2. As a result, NSP6 diminishes the antiviral efficacy of ACE2-exos and facilitates the virus to infect healthy bystander cells. Overall, our study provides a valuable target for the discovery of promising drugs for the treatment of coronavirus disease 2019. IMPORTANCE The outbreak of coronavirus disease 2019 (COVID-19) severely endangers global public health. The efficacy of vaccines and antibodies declined with the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants. Angiotensin-converting enzyme 2-containing exosomes (ACE2-exos) therapy exhibits a broad neutralizing activity, which could be used against various viral mutations. Our study here revealed that SARS-CoV-2 nonstructural protein 6 inhibited the production of ACE2-exos, thereby promoting viral infection to the adjacent bystander cells. The identification of a new target for blocking SARS-CoV-2 depends on fully understanding the virus-host interaction networks. Our study sheds light on the mechanism by which the virus resists the host exosome defenses, which would facilitate the study and design of ACE2-exos-based therapeutics for COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ExosomesHumansSARS-CoV-2Angiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AAntiviral AgentsSpike Glycoprotein, CoronavirusProtein Binding

Stichwörter der Autor:innen

ACE2CD63NSP6PSMD12SARS-CoV-2exosomes

Substanzen

Angiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AAntiviral AgentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
  • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-se…
  • Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, Guangdong, China.
  • Department of Breast Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Center for Infection and Immunity Studies, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, China.

ORCID-Profile: Xi Lv, Hui Zhang, Xiancai Ma

Förderung

  • R&D Programs of Guangzhou National Laboratory
  • MOST | National Natural Science Foundation of China (NSFC)
  • National Key R&D Program of Department of Science and Technology of China
  • Important Key Program of NSFC
  • Exchange Program of NFSC
  • Guangdong Basic and Applied Research Foundation
  • Emergency Key Program of Guangzhou National Laboratory

Zitieren

APA

Lv, X., Chen, R., Liang, T., Peng, H., Fang, Q., Xiao, S., Liu, S., Hu, M., Yu, F., Cao, L., Zhang, Y., Pan, T., Xi, Z., Ding, Y., Feng, L., Zeng, T., Huang, W., Zhang, H., & Ma, X. (2024). NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity. mBio. https://doi.org/10.1128/mbio.03358-23

Vancouver

Lv X, Chen R, Liang T, Peng H, Fang Q, Xiao S, et al. NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity. mBio. 2024. doi:10.1128/mbio.03358-23

BibTeX
@article{Lv2024,
  author = {Lv, Xi and Chen, Ran and Liang, Taizhen and Peng, Haojie and Fang, Qiannan and Xiao, Shiqi and Liu, Sen and Hu, Meilin and Yu, Fei and Cao, Lixue and Zhang, Yiwen and Pan, Ting and Xi, Zhihui and Ding, Yao and Feng, Linyuan and Zeng, Tao and Huang, Wenjing and Zhang, Hui and Ma, Xiancai},
  title = {NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.03358-23}
}
Kostenlos starten →